Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.
In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
Deal Snapshot: The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform.
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.
Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations.
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.
Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.
With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.
Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.